Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder

Neuropsychopharmacology

Volumn 39, Issue 11, 2014, Pages 2549-2559

  Brunner, Elizabeth ^a   Tohen, Mauricio ^b   Osuntokun, Olawale ^a   Landry, John ^a   Thase, Michael E ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DRUG COMBINATION; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SUICIDE; TIME; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FLUOXETINE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SECONDARY PREVENTION; SUICIDE; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84901083930     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.101     Document Type: Article

References (46)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association: Washington, DC, USA.
2. American Psychiatric Associati on (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition American Psychiatric Association: Washington, DC, USA.
3. Andersen SW, Clemow DB, Corya SA (2005). Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 66: 1468-1476.
4. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G et al (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22: 343-396.
5. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP (2005). Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 22: 68-76.
6. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
7. Bauer M, Whybrow PC, Angst J, Versiani M, Mö ller HJ (2002). World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biologica l treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5-43.
8. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hou gh DW (2011). Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. J Affect Disord 129: 252-260.
9. Blier P, Gobbi G, Turcotte JE, De Montigny C, Boucher N, Hebert C et al (2009). Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 19: 457-465.
10. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. Am J Psychiatry 167: 281-288.
11. Carpenter LL, Yasmin S, Price LH (2002). A double-blind, placebocontrolled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51: 183-188.
12. Connolly KR, Thase ME (2012). Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 17: 105-126.
13. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sange r TM et al (2003). Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week openlabel study. J Clin Psychiatry 64: 1349-1356.
14. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depr ession. Depress Anxiety 23: 364-372.
15. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ et al (2002). The impact of treatment-resistant depression on health care utilization and costs. J Clin Psych iatry 63: 963-971.
16. De Bartolomeis A, Perugi G (2012). Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: From acute mania to long-term maintenance. Expert Opin Pharmacother 13: 2027-2036.
17. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M (2008). The STAR D study: Treating depression in the real world. Cleve Clin J Med 75: 57-66.
18. Greden JF (2001). The burden of disease for treatment-resistant depression. J Clin Psychiatry 62: 26-31.
19. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS et al (2013). Seco nd-generation antipsychotics in the treatment of major depressive disorder: Current evidence. Expert Rev Neurother 13: 851-870.
20. Ishak WW, Greenberg JM, Cohen RM (2013). Predicting relapse in major depressive di sorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord 151: 59-65.
21. Kemp De Karayal ON Calabrese JR Sachs GS Pappadopulos E Ice KS et al 2012 Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles Eur Neuropsychop harmacol 22 123-131.
22. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV (2009). CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the man agement of major depressive disorder in adults. J Affect Disord 117: S1-S2.
23. Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O (2012). Comparison of long-term (at least 24 weeks) wei ght gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22: 157-165.
24. Maes M, Libbrecht I, Van Hunsel F, Campens D, Meltzer HY (1999). P indolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177-182.
25. McIntyre RS, O'Donovan C ( 2004). The human cost of not achieving full remission in depression. Can J Psychiatry 49: 10S-16S.
26. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
27. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized s tudy. Biol Psychiatry 55: 296-300.
28. Papakostas GI, Petersen T , Pava J, Masson E, Worthington JJ 3rd, Alpert JE et al (2003). Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: Prevalence and impact on treatment outcome. J Nerv Ment Dis 191: 444-449.
29. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al (2011). The Columbia-Suicide Severity Rating Scale (C-SSRS): Initial Validity and Internal Consistency Findings from Three Mu lti-Site Studies with Adolescents and Adults. Am J Psychiatry 168: 1266-1277.
30. Psychopharmacology Research Branch, National Institute of Mental Health (1976a ). Abnormal lnvoluntary Movement Scale (AIMS). In: Guy W (eds). ECDEU Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health: Rockville, Md, USA, 534-537.
31. Psychopharmacology Resea rch Branch, National Institute of Mental Health (1976b ). Clinical Global Impressions (CGI). In: Guy W (eds). ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health: Rockville, Md, USA, 217-222.
32. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA et al (2006). Effects of risperidone augmentation in patients with treatment-resistant depression: Results of openlabel treatment followed by double-blind continuation. Neuropsychopharmacology 31: 2505-2513.
33. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, S tewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR D report. Am J Psychiatry 163: 1905-1917.
34. Sheehan DV, Harn ett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11: 89-95.
35. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG et al (2001). A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131-134.
36. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M et al (2005). Olanza pine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66: 1289-1297.
37. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 45: 11-19.
38. Symbyax prescribing information (2013; http://pi.lilly.com/us/symbyax-pi.pdf.
39. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM et al (2007). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major d epressive disorder. J Clin Psychiatry 68: 224-236.
40. Trivedi MH (2004). The link between depression and physical symptoms. Prim Care Companion J Clin Psychiatry 6: 12-16.
41. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: Implications for clinical practice. Am J Psychia try 163: 28-40.
42. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB et al (2009). An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 70: 387-396.
43. US Department of Health and Human Services, Public Health Services, Agency for Healthcare Research and Quality (1993). Clinical Practice Guideline 5: Depression in Primary Care, Vol 2. Treatment of Maj or Depression Publication No. 93-0551US Department of Health and Human Services: Rockville, MD, USA Treatment of Maj or Depression Publication No. 93-0551US Department of Health and Human Services: Rockville, MD, USA.
44. Wade AG, Hä ring J (2010). A review of the costs associated with depression and treatment noncompliance: The potential benefits of online support. Int Clin Psychopharmacol 25: 288-296.
45. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2011). Continuation of quetiapine versus switching to placebo or lithium for ma intenance treatment of bipolar I disorder (Trial 144: A randomized controlled study). J Clin Psychiatry 72: 1452-1464.
46. Zyprexa prescribing information (2013; http://pi.lilly.com/us/zyprexa-pi.pdf.